Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bioventus Inc. filings document the formal disclosures of a Nasdaq-listed medical device company with Class A common stock registered under the Exchange Act. Recent Form 8-K reports furnish operating results and financial condition updates, including quarterly and annual earnings releases for the company’s active-healing product portfolio.
The company’s regulatory filings also cover proxy governance for annual stockholder meetings, board composition matters, emerging growth company status, credit arrangements entered into by Bioventus LLC and its subsidiaries, and product regulatory events such as FDA 510(k) clearance for TalisMann and StimTrial within the Peripheral Nerve Stimulation portfolio.
Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.
Bioventus Inc. director Philip G. Cowdy filed an amended insider report to correct a previously reported equity grant. A prior Form 4 had shown a grant of 9,000 restricted stock units, but the footnote explains this grant was not accepted. As of February 11, 2021, he held no non-derivative or derivative securities of Bioventus.
Bioventus Inc. SVP & CFO Mark Leonard Singleton exercised 13,000 Restricted Stock Units into Class A common stock on April 10, 2026. To cover tax obligations, 5,648 shares of Class A common stock were withheld at $9.06 per share. After these transactions, he directly holds 177,333 shares of Class A common stock. Each RSU represents a contingent right to receive one share and vests in four equal installments on each of the first four anniversaries of April 10, 2023, subject to continued service.
Bioventus Inc. executive Katrina J. Church, SVP & Chief Compliance Officer, exercised restricted stock units on April 10, 2026, receiving 4,300 shares of Class A common stock at a conversion price of $0.00 per share. Of these, 1,868 shares of Class A common stock were withheld at $9.06 per share to satisfy tax obligations, a non-market tax-withholding disposition. After these transactions, she directly owned 64,164 shares of Class A common stock. The footnotes explain that each RSU represents a right to receive one share of Class A common stock and that the RSUs vest in four equal installments on each of the first four anniversaries of April 10, 2023, subject to continued service.
Bioventus Inc. SVP & General Counsel Anthony D'Adamio exercised restricted stock units into shares of Class A common stock. On April 10, 2026, he converted 9,925 RSUs into 9,925 shares of Class A common stock at a conversion price of $0.00 per share.
To cover tax obligations related to this equity compensation, 4,312 shares of Class A common stock were disposed of at $9.06 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, he directly holds 153,655 shares of Class A common stock.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported routine equity compensation activity in the form of restricted stock units. On March 20, 2026, he exercised 18,625 RSUs, receiving the same number of shares of Class A common stock at a stated price of $0.00 per share.
To cover tax obligations related to this vesting, 8,091 shares of Class A common stock were withheld at $8.64 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, Singleton directly held 169,981 shares of Class A common stock.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported multiple equity compensation transactions in company stock. He received 104,000 restricted stock units and a stock option for 116,000 shares of Class A common stock at an exercise price of $8.6200 per share, both granted on March 13, 2026. He also reported earlier grants from March 14, 2025 of 54,000 RSUs and a stock option for 61,000 shares at $9.6100 per share. On the same 2026 date, he exercised 13,500 RSUs into 13,500 shares of Class A common stock, with 5,865 shares withheld to cover tax obligations. After these transactions, he directly holds 159,447 shares of Class A common stock. The RSUs and options vest in four equal annual installments starting on March 15, 2025 and March 15, 2026, subject to his continued service.
Bioventus Inc. senior vice president and chief compliance officer Katrina J. Church received new equity awards and exercised existing awards. On March 13, 2026 she was granted 24,000 restricted stock units and 27,000 stock options with an exercise price of $8.62 per share, all vesting in four annual installments starting March 15, 2026, subject to continued service.
Church also exercised a total of 6,955 restricted stock units into Class A common stock, with 3,022 shares withheld to cover tax obligations. After these transactions she directly holds 61,732 shares of Class A common stock, plus outstanding RSU and option awards disclosed in the filing.
Bioventus Inc. senior vice president and general counsel Anthony D'Adamio reported multiple equity compensation transactions in Class A common stock and related derivatives. On March 13, 2026, he received grants of 83,000 restricted stock units (RSUs) and 92,000 stock options with an exercise price of $8.62 per share, expiring on March 13, 2036. Each RSU represents a right to receive one share of Class A common stock. The RSUs and options granted in 2025 and 2026 vest in four equal annual installments beginning on March 15, 2025 and March 15, 2026, subject to his continued service. On the same 2026 date, he exercised 8,886 and 8,750 RSUs into the same number of Class A shares, and the company withheld 3,861 and 3,802 shares at a price of $8.62 per share to cover tax obligations. Following these transactions, he directly owned 148,042 shares of Bioventus Class A common stock.
Bioventus Inc. President and CEO Robert E. Claypoole reported equity compensation changes and an option-related share delivery. On March 13, 2026, he exercised 33,500 restricted stock units into 33,500 shares of Class A common stock at $0.00 per share and had 14,553 shares withheld at $8.62 per share to cover tax obligations, leaving 135,944 Class A shares held directly.
On the same date, he received grants of 278,000 restricted stock units and 309,000 stock options for Class A common stock, with the options carrying an exercise price of $8.62 and expiring on March 13, 2036. Footnotes state that the RSUs and options granted in 2025 and 2026 vest in four equal annual installments starting on the first four anniversaries of March 15, 2025 and March 15, 2026, subject to his continued service.
Bioventus Inc. director Michelle McMurry-Heath reported an open-market sale of 12,000 shares of Class A common stock. The shares were sold at a weighted average price of $8.7866, in multiple trades between $8.73 and $8.81. After the transaction, she directly holds 44,997 shares.